Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Clinical Intervention Awards, 2013
    Dipraglurant for Levodopa-Induced Dyskinesia Pre-phase IIB Studies

    Study Rationale:                   
    Dipraglurant is a modulator of the metabotropic glutamate receptor 5 (mGluR5). Blockade of this receptor has been shown to have anti-parkinsonian and anti-dyskinetic...

  • Neurotrophic Factors Challenge, 2013
    Exploring a Novel Neurotrophic Factor to Protect the Nigrostriatal Dopaminergic System and Alleviate Motor Deficits

    Objective/Rationale:             
    Safety and effectiveness in brain delivery remain two major challenges in developing novel neuroprotective agents to treat Parkinson’s disease (PD) patients. This...

  • Cognition Biomarkers, 2013
    Insulin-like Growth Factor-1 and DAT Imaging as Biomarkers of Early Cognitive Impairment in Parkinson’s Disease

    Objective/Rationale:        
    Evidence supports that the protein insulin-like growth factor-1 (IGF-1) may be involved in cognitive deficits. An earlier study found that low serum IGF-1 levels...

  • Rapid Response Innovation Awards, 2013
    Novel Quantification Paradigm in Parkinson’s Disease Neurochemical Imaging

    Objective/Rationale:             
    Parkinson’s disease imaging using dopamine transporter (DAT) single-photon emission computed tomography (SPECT) technology conveys important information on brain...

  • Rapid Response Innovation Awards, 2013
    Novel Method for Therapeutic Gene Silencing in the Brain

    Objective/Rationale:             
    Reducing the activity of certain genes — called gene silencing — implicated in Parkinson’s disease may be a therapeutic approach that could prevent or slow the disease...

  • Access to Data and Biospecimens, 2013
    Alpha-Galactosidase A and Glycosphingolipid Metabolites as Putative Biomarkers for Parkinson’s Disease

    Objective/Rationale:             
    Alpha Galactosidase A (alpha-Gal A) is an enzyme that is ordinarily responsible for lipid recycling in cells. Researchers have shown how pre-clinical models that lack...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.